Johnson & Johnson has dropped a pair of CAR-T cell therapies, axing programs it once predicted could deliver peak sales north ...

As the calendar turned from April to May, a big change came to the FDA. | Katherine Szarama, Ph.D., will take over as CBER ...

Genomics Ltd inked a partnership deal with fellow U.K.-based biotech Greywolf Therapeutics to organize and evaluate ERAP ...

Amgen has pulled the plug on midstage drug candidates for cancer and the autoimmune disease Sjögren’s syndrome, terminating ...

Viking Therapeutics’ collaboration with Ligand Pharmaceuticals has sailed into some trouble, with one of the partners keen to ...

Welcome to this week's Chutes & Ladders, our roundup of significant leadership hirings, firings and retirings across the ...

The FDA’s Oncologic Drugs Advisory Committee (ODAC) on Thursday voted 6 to 3 that AstraZeneca has not demonstrated its oral ...

A phase 2 trial of Indivior Pharmaceuticals’ opioid use disorder (OUD) candidate has missed its primary endpoint. Indivior ...

Avalyn Pharma has overshot its expectations with a $300 million IPO that the biotech will use to fund late-stage studies of ...

Bristol Myers Squibb has called time on a bispecific antibody partnership with Zymeworks that the Big Pharma inherited from ...

Danish dermatology specialist Leo Pharma is paying $50 million for U.S. gene writing biotech Replay and its preclinical gene ...

GSK and Alector have stopped a phase 2 trial of their Alzheimer’s disease drug candidate after an interim analysis found the ...